The value of pre-treatment with gonadotrophin releasing hormone (GnRH) analogue in IVF-ET therapy of severe endometriosis

article OA: closed CC0 ⤵ 38 in-corpus citations
View on OpenAlex View on PubMed View at publisher

Abstract

Controversy concerning the optimal treatment of endometriosis and its related infertility still exists. Thirty-one women with moderate and severe endometriosis, who failed to conceive during previous in-vitro fertilization and embryo transfer (IVF-ET) cycles (protocol A), were re-admitted for the procedure following a period of hormonal suppression with a gonadotrophin releasing-hormone (GnRH) agonist (protocol B). Following GnRH analogue treatment, a significantly higher number of oocytes were recovered (P < 0.0006); consequently more embryos were transferred and significantly higher clinical pregnancy rates per cycle (P < 0.0001) were achieved. This difference may be directly related to the beneficial effect of the GnRH analogue on pelvic endometriosis, converting severe cases into mild ones with improved ovarian accessibility and probably oocyte quality.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Buserelin Embryo Transfer Endometriosis Fertilization in Vitro Infertility, Female Buserelin Endometriosis Female Humans Infertility, Female Infertility, Female Oocytes Oocytes Pregnancy

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (38)

Source provenance

europepmc
last seen: 2026-07-01T06:12:12.862213+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:10.587122+00:00
unpaywall
last seen: 2026-06-30T06:26:37.652333+00:00
License: CC0 · commercial use OK